Table 5.

Baseline characteristics — control patients

Nr	Sex	Age	Tumour type	Treatment preceding ASL	Seizures preceding ASL	Score ASL
1	W	43	ODG 1p/19q, codel	No	Yes	1
2	W	49	ODG 1p/19q, codel	No	No	0
3	M	47	ODG 1p/19q, codel	No	No	0
4	M	48	DA IDH mt	No	Yes	0
5	M	50	DA IDH mt	No	Yes	0
6	M	40	DG-NOS	No	No	0
7	M	26	DA IDH mt	TMZ 9 cycles	No	1
8	W	52	DA IDH mt	No	No	0
9	W	38	DA IDH mt	No	No	0
10	M	25	DA IDH mt	RT 50.4 Gy, TMZ 12 cycles	No	0
11	W	44	DA IDH mt	RT 50.4 Gy, TMZ 11 cycles	No	0
12	M	57	DA IDH mt	RT 50.4 Gy, TMZ 12 cycles	No	0
13	W	45	DA IDH mt	RT 50.4 Gy	No	0
14	M	21	DA IDH mt	RT 50.4 Gy	No	0
15	W	21	DA IDH mt	RT 50.4 Gy	No	0
16	M	57	DA IDH mt	RT 50.4 Gy, TMZ 12 cycles	Yes	2
17	M	39	DA IDH mt	RT 50.4 Gy, TMZ 12 cycles	No	0
18	M	18	DA IDH mt	RT 50.4 Gy, TMZ 12 cycles	No	0
19	W	49	DA IDH mt	RT 50.4 Gy, TMZ 9 cycles	No	0
20	M	25	DA IDH mt	RT 50.4 Gy, TMZ 3 cycles	No	0
21	M	33	DA IDH mt	RT 50.4 Gy, TMZ 2 cycles	No	0
22	M	53	DA IDH mt	RT 50.4 Gy	No	1
23	M	32	DG-NOS	RT 50.4 Gy	No	0
24	W	27	DG-NOS	RT 50.4 Gy	No	0
25	M	50	DA IDH wt	RT 50.4 Gy, TMZ 8 cycles	No	0
26	M	31	DA IDH mt	RT 50.4 Gy	No	0
27	W	50	DG-NOS	RT 50.4 Gy, PCV 5 cycles	No	0
28	M	55	DA IDH wt	RT 50.4 Gy, TMZ 7 cycles	No	0
29	M	46	DA IDH mt	RT 50.4 Gy, TMZ 7 cycles	No	0
30	M	26	DA IDH mt	RT 50.4 Gy, TMZ 6 cycles	No	2
31	M	45	DA IDH wt	No	Yes	0
32	M	35	DA IDH mt	No	No	0
33	W	23	DA IDH mt	No	Yes	2

Nr, number of control patient; W, woman; M, man; Age, age at first diagnosis; ODG 1p/19q-codel, 1p/19q-codeleted oligodendroglioma; DA, diffuse astrocytoma; IDH, Isocitrate dehydrogenase; mt, mutated; wt, wildtype; DG-NOS, diffuse glioma not otherwise specified; ASL, arterial spin labeling MRI; Score ASL, of first radiologist; RT, radiotherapy; Gy, Gray; TMZ, temozolomide; PCV, procarbazine/lomustine/vincristine.